Pemphigoid gestationis treated with dupilumab
- PMID: 37842158
- PMCID: PMC10568228
- DOI: 10.1016/j.jdcr.2023.08.013
Pemphigoid gestationis treated with dupilumab
Keywords: corticosteroid-sparing therapy; dupilumab; immunobullous disease; pemphigoid gestationis; pregnancy related rash; pruritus.
Conflict of interest statement
Dr Anadkat has served as a Consultant and/or Advisor for ImClone, Bristol Myers Squibb, Astra Zeneca, Therakos, Aspire Bariatrics, Biogen, Amgen, Veloce, Adgero, Eli Lilly, Abbvie, UCB Biopharma, Innovaderm, Boehringer-Ingelheim, OnQuality, Novocure, Springworks, BioLinq, and Protagonist. MJA has served as a Principal Investigator for Novartis, Boehringer-Ingelheim, Lutris, OnQuality, UCB Biopharma, InflamRx, Eli Lilly, InCyte, Abbvie, Moonlake, AnaptysBio, Hana Biosciences, Xoma, Veloce, Biogen, Xbiotech, and Chemocentryx. Author Chen and Dr Yokoyama have no conflicts of interest to declare.
Figures
References
-
- Fong H., Gandhi G.R., Gharbi A., Hafsi W. StatPearls Publishing LLC; 2022. Pemphigoid Gestationis. StatPearls. - PubMed
Publication types
LinkOut - more resources
Full Text Sources